World Library  
Flag as Inappropriate
Email this Article

Leukocyte adhesion deficiency

Article Id: WHEBN0002791679
Reproduction Date:

Title: Leukocyte adhesion deficiency  
Author: World Heritage Encyclopedia
Language: English
Subject: CD18, Leukocyte adhesion deficiency-1, LAD, Lymphocyte function-associated antigen 1, CD11a
Publisher: World Heritage Encyclopedia

Leukocyte adhesion deficiency

Leukocyte-adhesion deficiency
Classification and external resources
OMIM 116920
eMedicine ped/1302
MeSH D018370

Leukocyte adhesion deficiency (LAD), is a rare autosomal recessive disorder characterized by immunodeficiency resulting in recurrent infections.[1] LAD is currently divided into three subtypes: LAD1, LAD2, and the recently described LAD3, also known as LAD-1/variant. In LAD3, the immune defects are supplemented by a Glanzmann thrombasthenia-like bleeding tendency.[2][3]


  • Characteristics 1
  • Cause and genetics 2
  • Diagnosis 3
  • Treatment 4
  • Epidemiology 5
  • See also 6
  • External links 7
  • References 8


LAD was first recognized as a distinct clinical entity in the 1970s. The classic descriptions of LAD included recurrent bacterial infections, defects in neutrophil adhesion, and a delay in umbilical cord sloughing. The adhesion defects result in poor leukocyte chemotaxis, particularly neutrophil, inability to form pus and neutrophilia.[3]

Individuals with LAD suffer from bacterial infections beginning in the neonatal period. Infections such as omphalitis, pneumonia, gingivitis, and peritonitis are common and often life-threatening due to the infant's inability to properly destroy the invading pathogens. These individuals do not form abscesses because granulocytes cannot migrate to the sites of infection.

Cause and genetics

Leukocyte-adhesion deficiency has an autosomal recessive pattern of inheritance.

Types include:

Type OMIM Gene
LAD1 116920 ITGB2
LAD2 or CDG2C 266265 SLC35C1
LAD3 612840 FERMT3

The most common type is LAD1.

The inherited molecular defect in patients with LAD1 is a deficiency of the β-2 integrin subunit,[4] also called CD18, which is encoded by the ITGB2 gene (found in chromosome 21). This subunit is involved in the formation of the β-2 integrins (LFA-1, Integrin alphaXbeta2, and Mac-1/CR3) by the dimerization with different CD11 subunits. Mutations in ITGB2 gene lead to absent, reduced or aberrant CD18 protein expression. The final results in the no expression in the leukocyte membrane of the β-2 integrins. The main function of these proteins in allowing neutrophils to make their way out of the blood stream to the infected tissues by adhering to different ligands expressed by the endothelium (e.g. ICAM-1). In LAD-I patients, neutrophils can not extravasate and fight against bacteria in the tissues. The bacteria can then proliferate, leading to symptomatic infection. The infection can spread unimpeded and cause serious injury to important tissue.


Typically, diagnosis is made after several preliminary tests of immune function are made, including basic evaluation of the humoral immune system and the cell-mediated immune system. A WBC differential will reveal extremely elevated levels of neutrophils (on the order of 6-10x normal) because they are unable to leave the blood vessels. In the case of LAD-I, specific diagnosis is done by flow cytometry. This technique will reveal absent or reduced CD18 expression in the leukocyte membrane. Recently, prenatal diagnosis systems has been established, allowing an early detection of the disease. LAD-II diagnosis includes the study of different glycosilated forms of the transferrin protein. In LAD-III, as platelet function is also affected, this could be used to differentiate it from the other types.


Although patients can receive intensive antibiotherapy and even granulocyte transfusions from healthy donors, the only current curative therapy is the hematopoietic stem cell transplant.[5] However, progress has been made in gene therapy, an active area of research. Both foamyviral and lentiviral vectors expressing the human ITGB2 gene under the control of different promoters have been developed and have been tested so far in preclinical LAD-I models (such as CD18-deficient mice and canine leukocyte adhesion deficiency-affected dogs).


LAD is a rare disease, with an estimated prevalence of one in 100,000 births, with no described racial or ethnic predilection. The most common type is LAD1.

See also

External links

  • Immune Deficiency Foundation
  • Leukocyte Adhesion Deficiency Web Site


  1. ^ "Leukocyte Adhesion Deficiency: Immunodeficiency Disorders: Merck Manual Professional". Retrieved 2008-03-01. 
  2. ^ Robert P, Canault M, Farnarier C, Nurden A, Grosdidier C, Barlogis V, … Alessi MC (2011). "A novel leukocyte adhesion deficiency III variant: kindlin-3 deficiency results in integrin- and nonintegrin-related defects in different steps of leukocyte adhesion". Journal of Immunology 186 (9): 5273–83.  
  3. ^ a b Abbas AK, Lichtman AH, Pillai S (2012). Cellular and molecular immunology (7th ed.). Philadelphia: Elsevier/Saunders.  
  4. ^ Kishimoto TK, Hollander N, Roberts TM, Anderson DC, Springer TA (1987). "Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency". Cell 50 (2): 193–202.  
  5. ^ van Vliet DN, Brandsma AE, Hartwig NG (2004). "Leukocyte-adhesion deficiency - a rare disorder of inflammation". Ned Tijdschr Geneeskd. 145 (50): 2496–2500.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.